Ownership and insider activity for Nutriband Inc. (NTRB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain.
Price
| Price | $7.04 |
| Market Cap | $86M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2025-01-31 | Sheridan Gareth | |||
| 2025-01-29 | Sheridan Gareth | A-Award | 29,333 | $237K |
| 2024-03-20 | Sheridan Gareth | A-Award | 97,500 | $254K |
| 2025-01-23 | Goodman Gerald | A-Award | 17,667 | $130K |
| 2024-03-19 | Goodman Gerald | A-Award | 75,000 | $145K |
| 2024-06-05 | Goodman Gerald | X-InTheMoney | 60,085 | $116K |
| 2024-03-20 | Goodman Gerald | A-Award | 75,000 | $178K |
| 2024-06-06 | Goodman Gerald | M-Exempt | 87,500 | $169K |
| 2024-03-20 | MELNIK SERGUEI | A-Award | 97,500 | $254K |
| 2024-03-20 | Sheridan Gareth | A-Award | 75,000 | $178K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $27124 | 0 | $474653 | $10181 | $151993 | $4.9M | $2.0M | $492942 | $4.3M | $4.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $229 | $263 | $13088 | $12833 | $109347 | $71380 | $113045 | $148649 | $73847 | $118404 |
| Inventory | $8048 | $4133 | 0 | $0 | $52848 | $131648 | $229335 | $168605 | $212041 | $117987 |
| Total Current Assets | $37727 | $164899 | $590466 | $43181 | $314188 | $5.5M | $2.7M | $1.0M | $4.8M | $5.0M |
| Property, Plant & Equipment | 0 | 0 | $146147 | $120639 | $1.1M | $998340 | $960489 | $806298 | $695063 | $639255 |
| Goodwill | 0 | 0 | $1.7M | $1.7M | $7.5M | $5.3M | $5.0M | $5.0M | $1.7M | $1.7M |
| Intangible Assets | 0 | 0 | $351770 | $314700 | $1.0M | $926913 | $780430 | $667280 | $261092 | $200427 |
| Total Assets | $37727 | $164899 | $2.8M | $2.2M | $9.9M | $12.7M | $9.5M | $7.5M | $7.5M | $7.5M |
| Accounts Payable | $4149 | $12341 | $291781 | $771931 | 0 | 0 | 0 | $680132 | $698821 | $502654 |
| Short-term Debt | $10469 | $31050 | $40000 | $311567 | $1.5M | $14119 | $19740 | $127182 | $128144 | $161324 |
| Total Current Liabilities | $14618 | $43391 | $403006 | $2.0M | $2.6M | $779256 | $748613 | $999093 | $982845 | $784281 |
| Long-term Debt | 0 | 0 | 0 | 0 | $150063 | $101119 | $100497 | $79826 | $58205 | $35861 |
| Total Liabilities | $14618 | $43391 | $403006 | $2.0M | $2.8M | $880375 | $883387 | $1.1M | $1.0M | $868447 |
| Retained Earnings | -$177464 | -$2.8M | -$6.2M | -$8.9M | -$11.8M | -$18.0M | -$22.5M | -$28.0M | -$38.5M | -$46.7M |
| Total Equity | $23109 | $121508 | $2.4M | $175433 | $7.1M | $11.9M | $8.6M | $6.4M | $6.4M | $6.7M |
| Total Debt | $10469 | $31050 | $40000 | $321617 | $1.8M | $134569 | $185805 | $241285 | $186349 | $245490 |
| Net Debt | -$16655 | $31050 | -$434653 | $311436 | $1.6M | -$4.8M | -$1.8M | -$251657 | -$4.1M | -$4.3M |
| Working Capital | $23109 | $121508 | $187460 | -$2.0M | -$2.3M | $4.7M | $1.9M | $22770 | $3.8M | $4.2M |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 4.21 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 27.17 |
Profitability
| Return on Equity | -109.02% |
| Return on Invested Capital | -126.99% |
| Return on Assets | -110.64% |
| Gross Margin | 33.14% |
| Operating Margin | -435.58% |
| Net Margin | -430.43% |
Related companies: ACET · ACRV · ADAG · CRVO · FBIO · GANX · LITS
Explore sector: Healthcare · Biotechnology
More sections of NTRB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks